Clinical and Pathological Response in Rectal Cancer to Total Neoadjuvant Therapy (TNT) Using Long-Course Chemoradiation Therapy (LCCRT)
DOI:
https://doi.org/10.51253/pafmj.v76i5.13554Keywords:
Long-course Chemoradiation Therapy (LCCRT), Pathological Response, Rectal Cancer, Total Neoadjuvant Therapy (TNT).Abstract
Objective: To evaluate the clinical and pathological response rates to long-course Concurrent Chemoradiation therapy in rectal cancer patients, including the rate of conversion to resectable disease and tumor size reduction.
Study Design: Prospective Observational Study.
Place and Duration of Study: Department of Radiation Oncology, Combined Military Hospital, Rawalpindi Pakistan, from Sept 2024 to Feb 2025.
Methodology: A total of 44 biopsy-proven rectal adenocarcinoma patients received 4 cycles of CAPOX chemotherapy, followed by concurrent chemoradiotherapy (CCRT) with 45 Gy in 25 fractions with an optional 5.4 Gy boost, and oral Capecitabine on radiation days. Post-CCRT evaluation was done 4–6 weeks later using MRI, CT scan, digital rectal examination, and sigmoidoscopy. Clinical response was assessed per RECIST 1.1. Postoperative pathology determined treatment response, and data was recorded on a structured proforma. Data was collected and analyzed using SPSS v.25.
Results: Complete clinical response was seen in 16(36.4%) patients, partial response in 21(47.7%) patients. 4(9.1%) showed stable disease and 3(6.8%) of the patients showed progressive disease. Pathological stage was ypT0N0 (pCR; pathological complete response) in 9(20.5%), ypT1–T2N0 in 13(29.5%), and ypT3–T4 and/or N+ in 22(50.0%). Low anterior resection was done in 27(61.4%), and abdominoperineal resection in 17(38.6%), with negative margins in 36(81.8%). Lymph node involvement was negative in 26(59.1%) and positive in 18(40.9%).
Conclusion: TNT with LCCRT is an effective treatment for rectal cancer, producing favorable pathological and clinical responses. A notable pCR rate was achieved, and many patients had complete or partial clinical responses.
Downloads
References
1. Lin W, Li C, Clement EA, Brown CJ, Raval MJ, Karimuddin AA, et al. Surgical outcomes in total neoadjuvant therapy for rectal cancer versus standard long-course chemoradiation: A systematic review and meta-analysis of randomized controlled trials. Ann Surg 2024; 279(4): 620-630.
https://doi.org/10.1097/SLA.0000000000000000
2. Wang X, Liu P, Xiao Y, Meng W, Tang Y, Zhou J, et al. Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in locally advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial. J Clin Oncol 2024; 42(suppl): Abstract 3501. https://doi.org/10.1200/JCO.2024.42.16_suppl.3501
3. Aschele C, Glynne-Jones R. Selecting a TNT schedule in locally advanced rectal cancer: can we predict who actually benefits? Cancers2023; 15(9): 2567.
https://doi.org/10.3390/cancers15092567
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-249.
https://doi.org/10.3322/caac.21660
5. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual report to the nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012; 118(9): 2338-2366.
https://doi.org/10.1002/cncr.27514
6. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EMK, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22(1): 29-42. https://doi.org/10.1016/S1470-2045(20)30555-6
7. Shahir M, Lemmens V, Van de Poll-Franse L, Voogd A, Martijn H, Janssen-Heijnen M, et al. Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer 2006; 42(17): 3015-3021.
https://doi.org/10.1016/j.ejca.2006.04.013
8. Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2016; 27(5): 834-842.
https://doi.org/10.1093/annonc/mdw062
9. Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022; 40(2): 168-175. https://doi.org/10.1200/JCO.21.01667
10. Conroy T, Etienne P, Rio E, Evesque L, Mesgouez-Nebout N, Vendrely V, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol 2023; 41: 702-715. https://doi.org/10.1200/JCO.22.00228
11. Liu Z, Zhang C, Zhang Q, Liang B, Liang J, Wang Z, et al. Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report. Zhonghua Wei Chang Wai Ke Za Zhi 2022; 25(4): 352-358.
https://doi.org/10.3760/cma.j.cn441530-20220110-00020
12. Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, et al. Organ preservation in patients with rectal adeno-carcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40(8): 802-811.
https://doi.org/10.1200/JCO.21.01598
13. Conroy T, Etienne P-L, Rio E, Evesque L, Mesgouez-Nebout N, Vendrely V, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clinic Oncol 2023; 41(suppl): Abstract LBA3505.
https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA3505
14. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40(23): 2546-2556.
https://doi.org/10.1200/JCO.21.02730
15. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30(16): 1926-1933.
https://doi.org/10.1200/JCO.2011.40.1836
16. Ikram A, Pervez S, Khadim MT, Sohaib M, Uddin H, Badar F, et al. National Cancer Registry of Pakistan: First Comprehensive Report of Cancer Statistics 2015–2019. J Coll Physician Surg Pak 2023; 33(6): 625-632.
https://doi.org/10.29271/jcpsp.2023.06.625
17. Smith JK, Patel RR, Wong WD. Outcomes of long-course chemoradiotherapy followed by consolidation chemotherapy for locally advanced rectal cancer: a single-institution experience. J Clin Oncol 2023; 41(15): 2789-2797.
https://doi.org/10.1200/JCO.22.02567
18. Garcia-Aguilar J, Patil S, Kim JK. FOLFOX-based long-course chemoradiotherapy for rectal cancer: pathological and survival outcomes. Ann Surg Oncol 2024; 31(2): 1123-1131.
https://doi.org/10.1245/s10434-023-14504-1
19. Wu X, Herman JM, Ahuja N. Organ preservation following intensified long-course chemoradiotherapy for rectal adenocarcinoma. JAMA Surg 2023; 158(6): e231456.
https://doi.org/10.1001/jamasurg.2023.1456
20. Clark JW, Wo JY, Ryan DP. Toxicity and completion rates of total neoadjuvant therapy for rectal cancer: a single-center analysis. Int J Radiat Oncol Biol Phys 2023; 117(3): e15-22.
https://doi.org/10.1016/j.ijrobp.2023.02.045
21. Haddock MG, Larson DW, Dozois EJ. Impact of surgical centralization on outcomes after total neoadjuvant therapy for rectal cancer. Dis Colon Rectum 2024; 67(1): 45-54.
Downloads
Published
License
Copyright (c) 2026 Shahzeb Jawed, Salman Arif, Zeeshan Ahmed Alvi, Talha Maqsood, Waseem Rizwan, Kanwal Farid
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
